It’s well known that early recurrence is an important adverse prognostic factor, which mainly results from dissemination of metastatic HCC cells [37, 38], thus detecting CASZ1 expression may help to predict HCC progression, and direct personalize therapy for HCC patients in the future. The gene discussed is CASZ1; the disease is hepatocellular carcinoma.